Paula Green Sells 935 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 935 shares of the company’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $46.43, for a total transaction of $43,412.05. Following the completion of the transaction, the senior vice president owned 124,401 shares of the company’s stock, valued at approximately $5,775,938.43. This trade represents a 0.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Paula Green also recently made the following trade(s):

• On Tuesday, February 3rd, Paula Green sold 1,194 shares of Twist Bioscience stock. The shares were sold at an average price of $46.58, for a total value of $55,616.52.
• On Monday, December 22nd, Paula Green sold 273 shares of Twist Bioscience stock. The shares were sold at an average price of $34.56, for a total value of $9,434.88.

Twist Bioscience Price Performance

NASDAQ TWST traded down $2.93 during trading hours on Tuesday, reaching $45.40. The company’s stock had a trading volume of 851,196 shares, compared to its average volume of 1,381,620. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of -35.47 and a beta of 2.23. The company’s 50-day moving average is $43.92 and its two-hundred day moving average is $34.80. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $57.88.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business had revenue of $103.70 million during the quarter, compared to analysts’ expectations of $100.32 million. The business’s revenue was up 16.9% compared to the same quarter last year. On average, equities analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently made changes to their positions in TWST. ARK Investment Management LLC lifted its position in Twist Bioscience by 12.4% during the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after buying an additional 832,687 shares in the last quarter. Artisan Partners Limited Partnership increased its stake in shares of Twist Bioscience by 26.7% in the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock worth $180,403,000 after acquiring an additional 1,349,867 shares during the last quarter. William Blair Investment Management LLC raised its holdings in shares of Twist Bioscience by 43.7% during the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after acquiring an additional 1,812,146 shares during the period. EdgePoint Investment Group Inc. boosted its position in shares of Twist Bioscience by 31.7% during the 4th quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock valued at $170,590,000 after acquiring an additional 1,295,672 shares during the last quarter. Finally, State Street Corp increased its position in Twist Bioscience by 17.4% during the fourth quarter. State Street Corp now owns 3,627,818 shares of the company’s stock worth $115,074,000 after purchasing an additional 538,755 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TWST. Robert W. Baird set a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, February 3rd. Evercore increased their target price on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Barclays increased their price objective on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, February 3rd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.88.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.